The prospect of patents expiring on lucrative drugs is prompting drugmakers to hunt for the next blockbuster medicines.

The prospect of patents expiring on lucrative drugs is prompting drugmakers to hunt for the next blockbuster medicines.

Biopharma dealmaking rebounds in Q2 2026: M&A nears $80B and licensing/R&D alliances hit a 5-year record $83B, per DealForma.